

DAFTAR PUSTAKA

1. Raskob GE, Hull DR, Buller. Venous Thrombosis. *Williams Hematology*, McGraw-Hill Companies Inc. 2010; 9e(133): 2700 – 2720.
2. Fauci AS, Kasper DL, Longo DL, et all. Venous Thrombosis. *Harrison's Principles of Internal Medicine*. 2008; 17(111): 786-798.
3. Lopez JA, Kearon C, Lee AYY. Deep Venous Thrombosis. *Hematology ASH Education Book*. 2004; 1: 439-456.
4. Hirsh J, Hull RD, Raskob GE. Epidemiology and Pathogenesis of Venous Thrombosis. *J Am. Coll. Cardiol.* 1986;8:104B-113B.
5. Richard H, White MD. The Epidemiology of Venous Thromboembolism. *Circulation*. 2003; 107:I-4 – I-8.
6. Naess IA, Christiansen SC, Romunstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb. Haemost*. 2007;5(4): 692-699.
7. Keenan CR, White RH. The effects of race/ethnicity and sex on the risk of venous thromboembolism. *Curr Opin Pulm Med*. 2007;13(5):377-383.
8. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of reccurent venous thromboembolism in men and women. *N Engl. J Med*. 2004;350(25):2558-2563.
9. Cushman M. Epidemiology and Risk Factors for Venous Thrombosis. *Semin Hematol*. 2007;44(2): 62–69.
10. Thomas JH. Pathogenesis Diagnosis, and Treatment of Thrombosis. *J Am. of Surgery*. 1990;160:547-551.
11. Kesieme E, Kesieme C, Dongo A, et al. Deep vein thrombosis : a clinical review. *J Blood Med*. 2011;2: 59-69.
12. Dairion G. Perbedaan akurasi skor Wells dengan Skor Padua dalam Diagnosis Deep Vein Trombosis, Spesialis Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Sumatera Utara, Medan. 2016; 1-27.
13. Setiabudy RD. Hemostasis dan trombosis. Badan Penerbit Fakultas Kedokteran Universitas Indonesia. 2012; 5: 143-154.
14. Mammen EF. The haematological manifestations of sepsis. *J Am. Coll*. 1998;4:A17–24.
15. Liaw PC, Esmon CT, Kahnamoui K. Patients with severe sepsis vary markedly in their ability to generate activated protein C. *Blood*. 2004;104:3958–3964.
16. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation: diagnostic criteria. *J Am. Hematol*. 2003;74:17–22.
17. Menik. Pemeriksaan koagulasi darah dan interpretasi. Buku Kedokteran EGC. 2011;1-20.
18. McKenna R, Bachmann F, Miro-Quesada M. Thromboembolism in patients with abnormally short austin time. *Thromb Haemost*. 1977;38:893–899.
Setiabudy RD. Fisiologi Hemostasis dan Fibrinolisis. Hemost dan Trombosis. *Balai* ;3: 1876-1883.
Upper Extremity Venous Thrombosis Diagnosed by Duplex Scanning, *J Am of Surgery*.



21. Fowler GC, Reddy B. Noninvasive Venous and Arterial Studies of the Lower Extremities. Pfenninger & Fowler's Procedures for Primary Care. *Philadelphia Elsevier Mosby*. 2011;3(88):1-6
22. Prandoni. DVT and the incidence of Subsequent Symptomatic cancer. *N. Eng J Med.* 1992;327:1128-1133.
23. Yanti KDF, Ni Nyoman M. Profil dan Perbandingan Hasil Diagnosis Klinis dengan Diagnosis Radiologi Deep Vein Thrombosis di RSUP Sanglah, Denpasar. *E-JURNAL MEDIKA UDAYANA*. 2015;4(2): 1-7.
24. Lubis RPS. Gambaran Risiko Trombosis Vena Dalam Berdasarkan Kriteria Wells pada Pasien Kanker di RSUP. Haji Adam Malik, Fakultas Kedokteran, Universitas Sumatera Utara, Medan. 2015; 1-37.
25. Song J, Kenneth J. Drobatz, et al. Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011). *JVECC*. 2016; 26(3): 1-8.
26. Korte W, Clarke S, Lefkowitz JB. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. *J Am Clin Pathol.* 2000;113:123–127.
27. Reddy NM, Hall SW, MacKintosh FR. Partial thromboplastin time. Prediction of adverse events and poor prognosis by low abnormal values. *Arch Intern Med.* 1999;159:2706–2710.
28. Yu M, Jonge ED, Poll TV. Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis. *Crit Care Med.* 2000;28:1777–1780.
29. Toh CH, Dennis M. Disseminated intravascular coagulation: old disease, new hope. *BMJ*. 2003;327:974–7.
30. Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. *Arterioscler Thromb Vasc Biol.* 2011; 31:e88–99.
31. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. *J Thromb Haemost.* 2003; 1:2677–2678.
32. Machlus KR, Cardenas JC, Church FC, et al. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. *Blood.* 2011; 117:4953–4963.
33. Ginsberg JS, Kearon C, Douketis J, et al. The Use of D-Dimer Testing and Impedance Plethysmographic Examination in Patients with Clinical Indications of Deep Vein Thrombosis. *Arch Intern Med*, 1997;5(157): 1077-1081.
34. Anderson DR, Wells PS, Stiell I, et al. Management of Patients with Suspected Deep Vein Thrombosis in the Emergency Department: Combining Use of a Clinical Diagnosis with D-Dimer Testing. *J Emerg Med.* 2000; 19(3): 225-230.
35. Aschwanden M, Labs KH, Jeanneret C, et al. Can a D-Dimer Assay, Alone or Combined with Structured Clinical Risk Assessment, Rule Out Deep Venous Thrombosis in Symptomatic Patients?. *J Vasc Surg.* 1999; 30:929-935.
36. Van der Graaf, van den Borne H, van der Kolk M, et al. Exclusion of Deep Venous Thrombosis with D-Dimer Testing. *Thromb Haemost.* 2000; 83:191-198
37. Perrier A, Desmarais S, Miron MJ, et al. Non-invasive Diagnosis of Venous Thromboembolism in Outpatients. *Lancet.* 1999; 353:190-195.



Grand'Maison A, Johnston M, et al. A Latex D-Dimer Reliability Excludes Venous Thromboembolism. *Arch Intern Med.* 2001; 161:447-453.

H. The Role of D-Dimer in the Diagnosis of Venous Thromboembolism. *Laboratory Medicine* :136-141.

40. Sudewo Y, Sahil MF, Edianto D, et al. Nilai Titik Potong D-Dimer Sebagai Penanda Terjadinya Trombosis Vena Dalam Pada Pasien Kanker Ovarium Sebelum Operasi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Sumatera Utara Medan, Indonesia. 2013; 1-15.
41. Skinner N, Mocan P. Deep Vein Thrombosis (DVT), Case Management Adherence Guidelines. *Case Manag Soc of Am*. 2007; 1-47
42. Ho C. Can very high level of D-dimer exclusively predict the presence of thromboembolic diseases?. *J Chin Med Assoc*. 2011; 74:151-154.
43. Barnes D, Wakefield T, Rectenwald J. Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review. *Biomarker Insights*. 2008; 3:93-100.
44. Brown T. Targeted D-Dimer Testing Best for DVT Diagnosis. *Medscape Med News*. 2013; 1-15.
45. Wells PS. Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. *N Engl. J Med*. 2003; 340:1227-1235.





KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
KOMITE ETIK PENELITIAN KESEHATAN

Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081225704670 e-mail : agussalimbukhari@yahoo.com

REKOMENDASI PERSETUJUAN ETIK

Nomor : 540/UN4.6.4.5.31/ PP36/ 2019

Tanggal: 25 Juli 2019

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH19060381	No Sponsor	
Peneliti Utama	dr. Erny Alasiry	Sponsor	
Judul Peneliti	Hubungan Skor Wells,Kadar PT,APTT,Fibrinogen, D-Dimer Dengan Hasil USG Doppler Pada Pasien Kecurigaan Deep Vein Thrombosis		
No Versi Protokol	2	Tanggal Versi	22 Juli 2019
No Versi PSP	2	Tanggal Versi	22 Juli 2019
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 25 Juli 2019 sampai 25 Juli 2020	Frekuensi review lanjutan
Wakil Komisi Etik Penelitian	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



